Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease

Trial Profile

Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs NLX P101 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neurologix
  • Most Recent Events

    • 12 Dec 2018 Results presented in a MeiraGTx media release.
    • 12 Dec 2018 According to a MeiraGTx media release, results from this study were published in the 2018 issue of Science Translational Medicine.
    • 09 Oct 2018 According to a MeiraGTx media release, results of this trial were published in the August 2014 issue of Journal of Clinical Investigation and the April 2017 issue of JCI Insight.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top